Löschmann, Nadine, Michaelis, Martin, Rothweiler, Florian, Zehner, Richard, Cinatl, Jaroslav, Voges, Yvonne, Sharifi, Mohsen, Riecken, Kristoffer, Meyer, Jochen, von Deimling, Andreas, Fichtner, Iduna, Ghafourian, Taravat, Frank Westermann, Frank Westermann and Cinatl, Jindrich (2013) Testing of SNS-032 in a panel of human neuroblastoma cell lines with acquired resistance to a broad range of drugs. Translational Oncology, 6 (6). pp. 685-696. ISSN 1936-5233 (doi:https://doi.org/10.1593/tlo.13544)

Preview

PDF (Elseiver Open Access Article. Further details at: http://www.elsevier.com/about/open-access/) (ITEM_11466)_SHARIFI_2013_SCI.pdf - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (2MB)

Abstract

Novel treatment options are needed for the successful therapy of patients with high-risk neuroblastoma. Here, we investigated the cyclindependent kinase (CDK) inhibitor SNS-032 in a panel of 109 neuroblastoma cell lines consisting of 19 parental cell lines and 90 sublines with acquired resistance to 14 different anticancer drugs. Seventy-three percent of the investigated neuroblastoma cell lines and all four investigated primary tumor samples displayed concentrations that reduce cell viability by 50% in the range of the therapeutic plasma levels reported for SNS-032 (<754 nM). Sixty-two percent of the cell lines and two of the primary samples displayed concentrations that reduce cell viability by 90% in this concentration range. SNS-032 also impaired the growth of the multidrug-resistant cisplatin-adapted UKF-NB-3 subline UKF-NB-3rCDDP1000 in mice. ABCB1 expression (but not ABCG2 expression) conferred resistance to SNS-032. The antineuroblastoma effects of SNS-032 did not depend on functional p53. The antineuroblastoma mechanism of SNS-032 included CDK7 and CDK9 inhibition–mediated suppression of RNA synthesis and subsequent depletion of antiapoptotic proteins with a fast turnover rate including X-linked inhibitor of apoptosis (XIAP), myeloid cell leukemia sequence 1 (Mcl-1), baculoviral IAP repeat containing 2 (BIRC2; cIAP-1), and survivin. In conclusion, CDK7 and CDK9 represent promising drug targets and SNS-032 represents a potential treatment option for neuroblastoma including therapy-refractory cases.

Item Type:	Article
Uncontrolled Keywords:	cell proliferation, cell viability, controlled study, flow cytometry, human cell, mitochondrial membrane potential, neuroblastoma, protein expression, protein phosphorylation, protein structure, RNA interference, RNA synthesis, systemic acquired resistance, tumor volume, Western blotting
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RS Pharmacy and materia medica
Faculty / School / Research Centre / Research Group:	Faculty of Engineering & Science Faculty of Engineering & Science > Medway School of Pharmacy
Related URLs:	Organisation Organisation
Last Modified:	19 Sep 2019 14:32
URI:	http://gala.gre.ac.uk/id/eprint/11466

Actions (login required)

View Item

Downloads